New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control
Ongoing
This early-stage study is testing the safety of combining two targeted cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or hasn't responded to at least two prior treatments. The main goal is to find the safest and most e…
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Apr 01, 2026 23:41 UTC